ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.60
-0.34%
US Tech 100
17,650.00
0.05%
S&P 500
5,222.68
0.16%
US Dollar vs CAD
1.36846
0.04%
Bitcoin
60,871.62
-0.94%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) News

AGEN

Agenus (AGEN)

Agenus Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AGEN
DateTimeSourceHeadlineSymbolCompany
05/07/20246:40AMBusiness WireAgenus Reports First Quarter 2024 ResultsNASDAQ:AGENAgenus Inc
05/07/20246:39AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
05/07/20246:38AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
05/07/20246:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
05/01/20246:30AMBusiness WireAgenus Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:AGENAgenus Inc
04/24/20249:00AMBusiness WireBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingNASDAQ:AGENAgenus Inc
04/23/20246:30AMBusiness WireAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
04/12/20246:30AMBusiness WireAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerNASDAQ:AGENAgenus Inc
04/05/20243:30PMBusiness WireAgenus Announces Reverse Stock Split of Common StockNASDAQ:AGENAgenus Inc
03/14/20246:30AMBusiness WireAgenus Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:AGENAgenus Inc
03/06/20246:30AMBusiness WireAgenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024NASDAQ:AGENAgenus Inc
03/05/20243:30PMBusiness WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
02/29/20243:50PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AGENAgenus Inc
02/29/20246:30AMBusiness WireAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportNASDAQ:AGENAgenus Inc
02/26/20243:24PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGENAgenus Inc
02/26/20246:30AMBusiness WireAgenus to Participate in Leerink Partners Global Biopharma ConferenceNASDAQ:AGENAgenus Inc
02/15/20247:02AMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGENAgenus Inc
02/15/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
02/15/20246:02AMPR Newswire (US)Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular DesignNASDAQ:AGENAgenus Inc
02/14/20247:33AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGENAgenus Inc
02/12/20246:00AMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
02/12/20246:00AMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
02/09/20244:11PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGENAgenus Inc
01/31/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
01/31/20246:30AMBusiness WireAgenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:AGENAgenus Inc
01/22/20248:59AMBusiness WireBotensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer PopulationNASDAQ:AGENAgenus Inc
01/22/20246:30AMBusiness WireBotensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer PopulationNASDAQ:AGENAgenus Inc
01/05/20243:30PMBusiness WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
01/04/20246:30AMBusiness WireAgenus to Participate in B. Riley Healthcare ConferenceNASDAQ:AGENAgenus Inc
01/04/20245:06AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
 Showing the most relevant articles for your search:NASDAQ:AGEN

Your Recent History

COIN
ENJGBP
Enjin Coin
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved